We use cookies to ensure that we give you the best experience on our website Learn more

Home

Saved research

Conference

Global Congress on Bladder Cancer 2020

October 10-15, 2020 · Online

22 submissions

Muscle invasive bladder cancer - are there any survival prognostic predictors?

muscle invasive

survival

bladder cancer

Can checkpoint inhibitor immune-related adverse events be a prognosis factor in urothelial cancer?

GIANT INFLAMMATORY MYOFIBROBLASTIC TUMOR OF URINARY BLADDER

ALK

inflammatory pseudotumor

BLADDER DIVERTICULUM CANCER

diverticulum bladder cancer

COVID-19 lockdown reduces screening and follow-up in urinary cytology

cytology

urine

lockdown

screening

prevention

G2ta bladder cancer without detrusor, do we need to restage at 6 weeks?

g2ta

WWOX–AP-2α interaction affects biology of bladder cancer and demonstrates usefulness in its clinical features’ discrimination.

AP-2α

bladder cancer

in vitro

in silico

Flexible blue light cystoscopy provides increased efficacy to manage non-muscle invasive bladder cancer in the outpatient clinic

bladder cancer

nmibc

blue light cystoscopy

Very low risk of severe complications after a single, post-operative instillation of intravesical chemotherapy in patients with low- or intermediate risk urothelial carcinoma of the bladder

Winner

urothelial carcinoma

Real-life experience in multimodal bladder preserving treatment for muscle-invasive bladder cancer

Multimodal bladder preserving treatment

Metastasis to the penis from a bladder carcinoma invading only the lamina propria: case report. Review of the literature and description of the metastatic pathways.

A rare case of recurrent paraganglioma of urinary bladder

bladder paraganglioma

Late recurrence following radical cystectomy with orthotopic ileal neobladder in NMIBC: A case report

orthotopic neobladder with recurrence

Phase 3 KEYNOTE-992 Study: Pembrolizumab Plus Chemoradiotherapy (CRT) Versus Placebo Plus CRT for Patients with Muscle-Invasive Bladder Cancer (MIBC)

pembrolizumab

PD-1

PD-L1

Perioperative Pembrolizumab or Placebo and Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer (MIBC) Who Are Eligible for Cisplatin (KEYNOTE-866 phase 3 study)

PD-1

PD-L1

pembrolizumab

Atezolizumab-induced myasthenia gravis in a patient with metastatic urothelial carcinoma

atezolizumab

immune-related adverse event

Perioperative Pembrolizumab or Pembrolizumab plus Enfortumab Vedotin (EV) and Cystectomy Compared to Cystectomy Alone in Patients With Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin-Ineligible (KEYNOTE-905/EV-303)

pembrolizumab

PD-1

PD-L1

enfortumab vedotin

UROTHELIAL CANCER. NEW THERAPIES, NEW TOXICITIES: MYASTHENIA GRAVIS

Toxicity

Inmunotherapy

Urothelial Cancer

Targeting antisense mitochondrial noncoding RNAs induces bladder cancer cell death and inhibition of tumor growth through reduction of survival and invasion factors

Submission not yet received

Intracorporeal Versus Extracorporeal Urinary Diversion Following Robot-Assisted Radical Cystectomy: A Meta-Analysis, Cumulative Analysis and Systematic Review

Submission not yet received

Winner

A new proteomic biomarker panel for bladder cancer stage differentiation by label-free quantitative high-resolution mass spectrometry.

Submission not yet received

Differential diagnosis of muscle-invasive and muscle-non-invasive bladder cancer using Raman spectroscopy (Raman spectroscopy).

Submission not yet received

Morressier

Company

Legal

Follow us

© Copyright 2020 Morressier GmbH. All rights reserved.

Home About Contact

Imprint Terms of Service Privacy Policy

Morressier

© Copyright 2020 Morressier GmbH.
All rights reserved.

Imprint Terms of Service Privacy Policy